Caplin Point Laboratories has secured approval from the U.S. Food and Drug Administration (USFDA) for its Milrinone Lactate Injection, a critical drug used in treating patients with severe heart failure. The regulatory clearance represents a significant step for the Chennai-based pharmaceutical company as it seeks to expand its footprint in the U.S. generics market.